Diagnosis of a genetic cause in hundreds of people with motor neuron disease (MND) could be missed due to “arbitrary age limits and rules” on genetic testing, a new study has revealed.
Based on the findings, researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London are calling for a complete rethink of the national guidelines surrounding who can access genetic testing for amyotrophic lateral sclerosis (ALS), also known as motor neuron disease.
The research suggests that there are hundreds of people with ALS in the UK for whom a genetic basis of their ALS is being missed as they do not fit the narrow requirements for genetic testing.
As guidelines are similar in many countries, this situation will likely be the same internationally, meaning potentially thousands of people being unaware of a genetic link to their ALS.
The research estimates that although nearly a quarter of people with ALS who do not have family members with the illness do have a genetic link to their ALS, this link goes undetected in 98 per cent of cases because of current guidelines.
As a result, they are not offered proper genetic advice and counselling, and would not be able to access gene-based therapies likely to be available soon or in trials. The researchers say that genetic testing should be open to all patients with ALS, regardless of whether or not other family members are affected, and for all ages.
Professor Ammar Al-Chalabi, Professor of Neurology and Complex Disease Genetics at King’s IoPPN, and the study’s lead author, said: “ALS is a condition that destroys lives. Genetic testing means that people and their families can be given correct advice and access to genetic counselling and be supported with family planning.
“Our study found that there are large numbers of people who are unable to access this care and support because of the arbitrary age limits and rules currently in place.”
ALS is a progressive nervous system disease that affects nerve cells in the brain and spinal cord, causing paralysis of muscles. Around 1 in 300 people will be diagnosed with ALS at some point in their lives, with the average person surviving for between two and five years after their symptoms begin. There is currently no cure for ALS.
In some cases, there is an identifiable genetic cause. Given the current restrictive testing guidelines, the researchers wanted to establish the probability of a positive genetic test result in various scenarios to provide evidence for how and when genetic testing should be used. They performed two analyses on global data sets, analysing the four most common ALS genes and a larger panel of 26 ALS genes.
Their analysis revealed that, by limiting testing in those without a family history to people with symptom onset below 40 years, as per current UK guidelines, 115 of 117 positive test results were missed.
Extrapolating this data to other health systems across the world, they found that potentially thousands of people with ALS will not know they have a genetic cause of their ALS due to the inaccessibility of testing.
While the researchers recognise that expanding the guidelines to include more people will be resource intensive, they argue that, where possible, countries should aim to offer genetic testing to ALS patients of all ages.
Dr Puja Mehta, the study’s first author, said “Our study shows the importance of being able to offer people with ALS of all ages a blood test to identify a possible genetic cause.
“In addition to accessing appropriate genetic counselling and support, with the exciting prospect of specific gene-based therapies on the horizon, and with clinical trials underway, it will become all the more important for people with ALS to know if they have an identifiable genetic cause.”
Dr Nicholas Cole, head of research at the MND Association, said: “This research, supported by the MND Association, adds weight to the suggestion that routine genetic testing should be offered to MND patients, regardless of their age at onset or family history of the disease.
“Genetic testing could provide opportunity for more people with MND to be involved in tailored clinical trials. However, it is imperative that testing is supported by a robust genetic counselling infrastructure to provide tailored support to all those who choose to embark upon this process.”
- Legal3 weeks ago
Understanding cauda equina syndrome and your legal options
- Brain injury case management4 days ago
Come and connect with the Kindred Community
- Neurophysiotherapy news4 weeks ago
Meet the PT: Rowan Morgan-Ruffley
- Neurophysiotherapy news2 weeks ago
Meet the therapist: Gemma Eves, Neuro Massage
- Brain injury news3 weeks ago
Brain and spine injury technology research centre set to launch
- Spinal injury news1 week ago
“How can this be happening in this day and age?” – SCI survivor calls for gender equity in healthcare
- Brain injury news3 weeks ago
Amnesia caused by head injury could be reversed, finds study
- Community neuro rehab3 days ago
Chroma partnership will make holidays for accessible to neurodiverse community